CMPS
Compass Pathways is a biotechnology company focused on accelerating patient access to evidence-based innovations in mental health care. The company studies investigational psilocybin therapies for treatment-resistant depression, post-traumatic stress disorder, and anorexia nervosa, aiming to advance clinical science and therapeutic options. Headquartered in London, the organization engages in global research collaborations and publishes results from its COMP360 program and related trials. Compass emphasizes patient-centric approaches and responsible clinical development in neuroscience-driven mental health treatment.